Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)

Historic Liabilities from Discontinued Operations for Anika Therapeutics (ANIK) over the last 2 years, with Q4 2024 value amounting to $4.1 million.

  • Anika Therapeutics' Liabilities from Discontinued Operations fell 6182.98% to $4.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.1 million, marking a year-over-year decrease of 6182.98%. This contributed to the annual value of $4.1 million for FY2024, which is 6182.98% down from last year.
  • As of Q4 2024, Anika Therapeutics' Liabilities from Discontinued Operations stood at $4.1 million, which was down 6182.98% from $10.8 million recorded in Q4 2023.
  • Anika Therapeutics' Liabilities from Discontinued Operations' 5-year high stood at $10.8 million during Q4 2023, with a 5-year trough of $4.1 million in Q4 2024.